ResMed Inc. (NYSE:RMD) Given New $70.00 Price Target at BMO Capital Markets

ResMed Inc. (NYSE:RMD) had its price objective raised by BMO Capital Markets from $61.00 to $70.00 in a research note issued to investors on Wednesday. They currently have a market perform rating on the medical equipment provider’s stock.

Other equities analysts have also recently issued reports about the company. BidaskClub cut ResMed from a strong-buy rating to a buy rating in a research note on Monday, July 24th. Zacks Investment Research upgraded ResMed from a hold rating to a buy rating and set a $87.00 price objective on the stock in a research note on Thursday, July 6th. Citigroup Inc. upgraded ResMed from a neutral rating to a buy rating in a research note on Wednesday. Credit Suisse Group cut ResMed from an outperform rating to a neutral rating in a research note on Wednesday. Finally, Bank of America Corporation cut ResMed from a buy rating to a neutral rating in a research note on Wednesday. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $65.63.

Shares of ResMed (NYSE RMD) traded up 1.30% during trading on Wednesday, reaching $73.45. 1,243,957 shares of the company were exchanged. ResMed has a one year low of $56.59 and a one year high of $79.63. The firm’s 50 day moving average price is $77.30 and its 200 day moving average price is $71.87. The company has a market capitalization of $10.42 billion, a PE ratio of 26.05 and a beta of 0.83.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.02. ResMed had a return on equity of 22.55% and a net margin of 16.56%. The business had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. During the same period last year, the business earned $0.74 EPS. The business’s revenue was up 7.3% on a year-over-year basis. Equities research analysts forecast that ResMed will post $3.06 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (NYSE:RMD) Given New $70.00 Price Target at BMO Capital Markets” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/04/resmed-inc-nysermd-given-new-70-00-price-target-at-bmo-capital-markets.html.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be paid a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.91%. This is a boost from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date of this dividend is Tuesday, August 15th. ResMed’s payout ratio is presently 54.77%.

In other news, insider James Hollingshead sold 7,140 shares of ResMed stock in a transaction on Friday, July 14th. The stock was sold at an average price of $77.43, for a total transaction of $552,850.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $77.49, for a total value of $96,862.50. Following the sale, the chief financial officer now owns 59,258 shares in the company, valued at $4,591,902.42. The disclosure for this sale can be found here. Insiders have sold a total of 153,896 shares of company stock worth $11,753,799 over the last quarter. Company insiders own 1.97% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA boosted its stake in ResMed by 58.4% in the second quarter. BNP Paribas Arbitrage SA now owns 78,102 shares of the medical equipment provider’s stock worth $6,082,000 after buying an additional 28,801 shares during the last quarter. Comerica Bank boosted its stake in ResMed by 0.7% in the second quarter. Comerica Bank now owns 125,554 shares of the medical equipment provider’s stock worth $9,691,000 after buying an additional 854 shares during the last quarter. Legal & General Group Plc boosted its stake in ResMed by 7.5% in the second quarter. Legal & General Group Plc now owns 760,102 shares of the medical equipment provider’s stock worth $59,189,000 after buying an additional 53,156 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in ResMed by 1.2% in the second quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock worth $176,505,000 after buying an additional 25,925 shares during the last quarter. Finally, State of Wisconsin Investment Board boosted its stake in ResMed by 31.6% in the second quarter. State of Wisconsin Investment Board now owns 121,929 shares of the medical equipment provider’s stock worth $9,495,000 after buying an additional 29,310 shares during the last quarter. Institutional investors own 60.65% of the company’s stock.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Analyst Recommendations for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

two × three =